Prothena Total Assets 2011-2022 | PRTA

Prothena total assets from 2011 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Prothena Annual Total Assets
(Millions of US $)
2021 $609
2020 $333
2019 $419
2018 $499
2017 $496
2016 $460
2015 $385
2014 $304
2013 $182
2012 $129
2011 $4
2010 $0
Prothena Quarterly Total Assets
(Millions of US $)
2022-03-31 $581
2021-12-31 $609
2021-09-30 $633
2021-06-30 $436
2021-03-31 $380
2020-12-31 $333
2020-09-30 $356
2020-06-30 $379
2020-03-31 $399
2019-12-31 $419
2019-09-30 $451
2019-06-30 $462
2019-03-31 $460
2018-12-31 $499
2018-09-30 $525
2018-06-30 $563
2018-03-31 $607
2017-12-31 $496
2017-09-30 $538
2017-06-30 $579
2017-03-31 $582
2016-12-31 $460
2016-09-30 $480
2016-06-30 $503
2016-03-31 $491
2015-12-31 $385
2015-09-30 $399
2015-06-30 $411
2015-03-31 $290
2014-12-31 $304
2014-09-30 $314
2014-06-30 $312
2014-03-31 $204
2013-12-31 $182
2013-09-30 $108
2013-06-30 $118
2013-03-31 $124
2012-12-31 $129
2012-09-30 $0
2012-06-30 $0
2012-03-31 $0
2011-12-31 $4
2010-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.268B $0.201B
Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis and a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A?.?Prothena is also developing candidates in collaboration with bigwigs like Roche and Bristol-Myers Squibb. These programs include prasinezumab, in collaboration with Roche for the potential treatment of Parkinson's disease and other related synucleinopathies, and programs that target tau, TDP-43 and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer's disease, amyotrophic lateralsclerosis, etc. It sold PRX004 and the broader ATTR amyloidosis program to Novo Nordisk. It derives revenues from license, development & commercialization agreements.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00